Ethos Biosciences
Rich Quashne currently serves as the Chief Operating Officer at Ethos Biosciences, a position held since July 2025. Prior to this, Rich Quashne was the President of Eurofins, overseeing significant developments such as the acquisition and establishment of the Horsham Campus, which consolidated four Eurofins entities. During tenure at Gold Standard Diagnostics Horsham, Rich Quashne achieved over 30% compound annual growth rate in revenues and earnings. Earlier experience includes roles such as Vice President/General Manager at Eurofins Abraxis and Global Marketing Manager at BD, along with positions at Optum, Weir Environmental Group, Agilent Technologies, Thomas Scientific, and SDIX, LLC. Rich Quashne holds an MBA in Finance from the University of Delaware and a BS in Biochemistry from the University of Richmond.
This person is not in any teams
This person is not in any offices
Ethos Biosciences
Ethos Biosciences designs, develops, and manufactures diagnostics that are accurate, repeatable, and easy to use. Ethos Biosciences was formed as a subsidiary of Ott Scientific in 2018 to drive healthcare innovation by providing diagnostic tools for scientists and practitioners. In November 2018, Ethos Biosciences acquired the Exocell diagnostic operation in Philadelphia from Glycadia Pharmaceuticals. Exocell was founded in 1988 by Dr. Margo Cohen, MD/PhD to explore diagnostic and therapeutic solutions for diabetes. Exocell quickly became a leader in nephrology diagnostics with 15 patents and over 2000 research citations. The Exocell brand continues to service the top research, academic, and industrial institutions in the world. Ott Scientific is a family owned and operated group of specialty chemical manufacturing companies with expertise in monomers, polymers, microspheres, and reagents for the pharmaceutical, medical device, and diagnostic industries.